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ABSTRACT
Evidence accumulated over recent years has shown that
genetic neurological channelopathies can cause many
different neurological diseases. Presentations relating to
the brain, spinal cord, peripheral nerve or muscle mean
that channelopathies can impact on almost any area of
neurological practice. Typically, neurological
channelopathies are inherited in an autosomal dominant
fashion and cause paroxysmal disturbances of
neurological function, although the impairment of
function can become ﬁxed with time. These disorders
are individually rare, but an accurate diagnosis is
important as it has genetic counselling and often
treatment implications. Furthermore, the study of less
common ion channel mutation-related diseases has
increased our understanding of pathomechanisms that is
relevant to common neurological diseases such as
migraine and epilepsy. Here, we review the molecular
genetic and clinical features of inherited neurological
channelopathies.
INTRODUCTION
Inherited disorders of ion channel function—the
‘genetic channelopathies’ are a rapidly expanding
group of neurological disorders and are implicated
in many areas of neurological practice. Although
the inherited channelopathies are individually rare,
the study of these conditions is contributing to our
understanding of pathomechanisms of neurological
disease in general.
Ion channels are specialised pore-forming pro-
teins that allow the passage of certain ions across
the lipid bilayer of the cell membrane. They are
typically divided into two broad categories accord-
ing to their method of activation—voltage or
ligand gated. The ‘gating’ of ion channels by trans-
membrane voltage changes or speciﬁc receptor
ligands, such as acetylcholine (ACh), together with
their selectivity for distinct ion species, underlies
the coordination of ion ﬂuxes during action poten-
tials or following neurotransmitter release.1
Most ion channels have a similar basic structure
—for example, all voltage-gated ion channels have
a large pore-forming subunit—the α subunit, com-
posed of four homologous domains (I–IV)—each
composed of six transmembrane segments (S1–S6).
In all cation channels, the S4 segments contain
between four and eight positively charged residues
conferring voltage dependence, and the S5-S6
loops form the ion pore. Ion channels are also
composed of several accessory subunits that may be
cytoplasmic or extracellular that have roles in
channel kinetics and membrane stabilisation2
(ﬁgure 1).
Although ion channels are essential for the
normal function of all eukaryotic cells, they are
particularly important in the nervous system for
the generation, repression and propagation of
action potentials. Ion channels are often highly
selective for a particular ionic species, for example,
sodium, potassium or calcium. The opening of
sodium channels leads to depolarisation of neurons
whereas potassium channel opening leads to hyper-
polarisation, as does the opening of chloride chan-
nels in adult neurons. The opening of calcium
channels causes membrane depolarisation, but
calcium ions also have more important roles as
second messengers.3 Hence, loss of function muta-
tions in potassium or chloride channels or gain of
function mutations should lead to disorders charac-
terised by hyperexcitability, such as epilepsy.
However, the effect of a mutation depends on the
speciﬁc neuronal circuitry involved. For example, a
mutation that causes a gain of function effect in
inhibitory interneurons can decrease excitability.3
Given their importance in neuronal excitability
and synaptic transmission through the central and
peripheral nervous systems, it is not surprising that
mutations in ion channel genes can lead to disease.
Many of the mutations that have been associated
with ion channel disorders are missense mutations
that affect channel kinetics. However, inherited
mutations and chromosomal rearrangements can
affect any stage of ion channel biogenesis, including
transcription, mRNA processing, splicing, transla-
tion, folding and trafﬁcking, as well as subunit
assembly.
Inherited disorders of ion channels are typically
inherited in an autosomal dominant fashion,
although there are exceptions, and can cause a
variety of neurological syndromes. Typically, symp-
toms begin relatively early in life and are paroxys-
mal or episodic, although a ﬁxed deﬁcit may
develop with time. These attacks or paroxysms are
often precipitated by various triggers. Stress, of
some form, is a frequent trigger, whereas certain
triggers are disease speciﬁc, such as heat in primary
erythromelalgia (PE), or rest after exercise or a
carbohydrate load in periodic paralysis. Mutations
in ion channels can alter channel function such that
homoeostasis cannot be maintained in the presence
of certain stimuli that would usually be innocuous.4
In this review, we describe the clinical character-
istics and genetics of inherited channelopathies of
the brain, spinal cord, peripheral nerve and muscle
(see online supplemental ﬁgure S1).
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CHANNELOPATHIES OF THE CENTRAL NERVOUS SYSTEM
Epilepsy
Although rare, inherited channelopathies account for a substan-
tial fraction of Mendelian epilepsy syndromes and can cause a
variety of epilepsy types ranging from severe infantile encephal-
opathies to relatively benign focal seizures (table 1).
Channelopathies associated with epileptic encephalopathies
Early onset epileptic encephalopathies are generally severe epilepsy
syndromes that often have a poor neurodevelopmental outcome.
Severe myoclonic epilepsy of infancy, also known as Dravet
syndrome, manifests as intractable seizures that begin in the ﬁrst
year of life associated with developmental regression and cogni-
tive impairment.5 6 Missense or nonsense mutations in the
SCNA1 gene which encodes the pore-forming unit of the fast
sodium channel NaV1.1 are present in over 80% of cases and
are typically de novo, leading to haploinsufﬁciency.7 8 More
rarely, mutations in other genes including SCN1B and SCN2A
have been found, as well as mutations in the GABAA receptor
subunit gene GABRG2.9–11 For some time, it was not under-
stood how a mutation in a sodium channel leading to haploin-
sufﬁciency and reduced function could cause hyperexcitability.
However, it was subsequently found that NaV1.1 channels have
an important role in GABAergic inhibitory neurons, thus loss of
function of these channels leads to hypoexcitability of inhibitory
networks and consequently hyperexcitability of neuronal net-
works and in turn, epilepsy.12
SCN2A mutations have also been associated with other
infantile encephalopathies including infantile spasms, acute
encephalitis with refractory repetitive partial seizures, Ohtahara
syndrome and recurrent encephalopathy.13 14 Intractable child-
hood epilepsy with generalised tonic-clinic seizures is a similar
disorder to Dravet syndrome and is also associated with muta-
tions in SCN1A.15 Recently, mutations of GABRA1, GABRB2
and GABRB3 were associated with infantile spasms and
Lennox-Gastaut syndrome.16 17
Migrating partial seizures of infancy is a rare infantile enceph-
alopathy that presents with focal seizures in the ﬁrst 6 months
of life, associated with acquired microcephaly and developmen-
tal stagnation or delay. This condition is genetically heteroge-
neous, with mutations in the KCNT1 gene that codes for a
sodium-activated potassium channel and mutations in SCN1A
both described.18 19
Mutations in SCN8A as well as KNCQ2 have been associated
with severe epileptic encephalopathies.20–22 Some cases of
DEND syndrome, (developmental delay, epilepsy and neonatal
diabetes) are caused by mutations in KCNJ11 which encodes
the Kir 6.2 subunit of the ATP-sensitive potassium channel.23 24
Generalised epilepsy syndromes
Generalised epilepsy with febrile seizures plus is a genetically
and clinically heterogeneous familial epilepsy syndrome.25
Individuals develop febrile seizures early in life that persist
beyond the age of 6 years. Numerous different genes have been
implicated; namely the sodium channel genes SCN1A, SCN1B,
SCN2A and the GABAA receptor subunit genes GABRG2 and
GABRD.26–30
Benign familial neonatal infantile seizures is an epilepsy syn-
drome characterised by sudden onset and subsequent remission
of seizures in infancy.31 32 It is caused by missense mutations in
the SCN2A gene.8 Benign familial neonatalconvulsions (BFNC)
is a similar syndrome characterised by brief seizures, occurring
on the second or third day after birth that usually terminate
within 6 weeks with normal neurological development.33 34 It
can be caused by loss of function mutations in two potassium
channel genes, KCNQ2 and KCNQ3, which code for the potas-
sium channel subunits KV7.2 and 7.3, respectively.
35–38 Proteins
encoded by these genes co-assemble to form a slowly activating
and deactivating potassium channel that plays a critical role in
regulating the excitability of neurons.39
A syndrome of generalised epilepsy with paroxysmal move-
ment disorders has been shown to be caused in one kindred by a
dominant missense mutation in the calcium-activated potassium
channel gene KCNMA1.40
Absence epilepsy has been reported in association with muta-
tions in a number of different genes that code for ion channels.
Variants in CACNA1H which codes for the α1H pore-forming
subunit of T-type calcium channels have been reported, in a
subset of patients with childhood absence epilepsy.41 However,
mutations have not been found to fully segregate with disease,
and the signiﬁcance of these variants remains unclear.42
Missense mutations of GABRA1, GABRA6, GABARB3 and
GABARG2 which encode various GABAA receptor subunits
have also been implicated in childhood absence epilepsy.43–45
Missense mutations of GABRA1 and GABRD have been
described in familial juvenile myoclonic epilepsy.30 46 Likewise,
Figure 1 (A) Structure of the α subunit of the voltage-gated sodium channel NaV1.1 encoded by SCN1A. The subunit is composed of four
domains (I–IV), which are each composed of six transmembrane subunits (S1–S6)—the positive gating charges in the S4 subunit are marked as is
the pore region (between S5 and S6). (B) Schematic representation of ion channel in open and closed states.
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mutations in GABRA1 and GABRG2 have been associated with
idiopathic generalised epilepsy (IGE).47
Recently exome sequencing revealed a mutation in KCNA2
which encodes the potassium voltage-gated channel subfamily A
member 2 in a young boy who presented in infancy with ataxia
and myoclonic epilepsy.48
Focal epilepsy syndromes
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)
is a rare syndrome characterised by frequent short-lived motor
seizures that typically occur during sleep or on waking.33 49 50
Mutations in three genes encoding subunits of the nicotinic
acetylcholine receptor (AChR), CHRNA4, CHRNB2 CHRNA2,
have been described in ADNFLE.49–56 Most mutations of the
AChR channel gene are located in the pore-forming domain and
are associated with a gain of function effect.57 58
A missense mutation in SCN3A, which encodes the α subunit
of NaV1.3, has been described in one patient with complex
partial seizures. Functional analysis showed that the mutated
channel results in prolonged action potentials in neurons expres-
sing Nav1.3.
59
Epileptic channelopathies: remaining questions
Epilepsy is a very common condition but monogenic channelo-
pathies only account for a small fraction of the epilepsy seen in
clinical practice. Although most epilepsies are not inherited in a
Mendelian fashion, it is estimated that about 70% of an indivi-
dual’s risk of developing a disorder such as epilepsy is accounted
for by genetic risk factors.60
Large-scale exome screening for ion channel variants in epi-
lepsy has led to the identiﬁcation of mutations/targets in genes
that were previously unexpected to have a role in epilepsy.
Single nucleotide polymorphisms in the chloride channel genes
CLCN1 and CLCN2 were found in three times as many patients
with epilepsy compared with controls.61 CLCN1 was previously
thought of as the ‘skeletal muscle chloride channel’ and was not
thought to be expressed in the brain. However, molecular local-
isation revealed widespread presence of the ClC-1 subunit
protein in the mouse and human brain, indicating that it may
contribute to the regulation of brain excitability and hence may
be implicated in epilepsy syndromes.61 Further large-scale
genetic studies are likely to lead to the identiﬁcation of other
candidate genes.
Table 1 Epilepsy syndromes caused by inherited mutations in ion channel genes
Channel Gene Channel Epilepsy syndrome(s)
Sodium SCN1A α subunit of NaV1.1 Severe myoclonic epilepsy of infancy (SMEI)
Intractable epilepsy with generalised tonic-clonic seizures (IEGTC)
Migrating partial seizures of infancy (MPSI)
Generalised epilepsy with febrile seizures (GEFS+)
SCN1B β subunit of NaV1.1 SMEI
GEFS+
SCN2A α2 subunit of NaV1.2 SMEI
Ohtahara syndrome
Benign familial neonatal infantile seizures (BFNIS)
West syndrome
Infantile spasms
GEFS+
SCN3A α3 of NaV1.3 Partial epilepsy
SCN8A α8 subunit of NaV1.6 Infantile epileptic encephalopathy
Potassium KCNQ2 KV7.2 Benign familial neonatal convulsions
Infantile encephalopathy
Myokymia associated with neonatal or early infantile epilepsy
KCNQ3 KV7.3 Benign familial neonatal convulsions
KCNMA1 Calcium-activated potassium
BK (Big Potassium) channel
Generalised epilepsy with paroxysmal movement disorder
KCNA1 KV1.1 Epilepsy with episodic ataxia
KCNA2 KV1.2 Myoclonic epilepsy and ataxia
KCNJII Kir6.2 Developmental delay, epilepsy and neonatal diabetes mellitus
(DEND syndrome)
KCNT1 Sodium-activated potassium channel MPSI
Calcium CACNA1H α subunit of t-type calcium channels Childhood absence epilepsy
CACNA1A CaV2.1 channel α subunit Episodic ataxia and childhood absence epilepsy
Acetylcholine receptor
(AChR)
CHRNA4, CHRNB2 CHRNA2 Subunits of nicotinic AChr receptor Autosomal dominant familial nocturnal frontal lobe epilepsy
GABA GABRA1 α subunit of GABA receptor Childhood absence epilepsy
Idiopathic generalised epilepsy (IGE)
Juvenile myoclonic epilepsy (JME)
Infantile spasms, Lennox-Gastaut
GABRB2 B2 subunit of the GABA receptor Infantile spasms, Lennox-Gastaut
GABRB3 β3 subunit of GABA receptor Absence epilepsy
Infantile spasms, Lennox-Gastaut
GABRD δ subunit of GABA receptor GEFS+
JME
GABRG2 γ2 subunit of GABA receptor GEFS+
SMEI
Childhood absence epilepsy
IGE
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However, to date, exome sequencing and large-scale genotyp-
ing studies of IGE have been disappointing.62 A possible explan-
ation for the genetics of sporadic epilepsy is that many cases
arise from polygenic inheritance, where several variants interact
to lower the seizure threshold. Modelling the possible effect of
combinations of ion channel mutations in preclinical systems to
demonstrate possible pathogenicity is complex and is a major
research challenge.
Treatment of epileptic channelopathies
A complete analysis of treatment in all the various epilepsy syn-
dromes caused by channelopathies is beyond the scope of this
review. It is clear however that increased understanding of
channel dysfunction in various epilepsy syndromes can lead to
an individualised approach to treatment. For example, func-
tional work on mutations in KCNQ2 have shown that the func-
tional changes (decreased voltage sensitivity) can be restored by
retigabine, a neuronal KV7 activator.
63 It has also been recog-
nised for some time that medications that block sodium channel
function can worsen seizures in SMEI.8 With further research,
there is potential for precision medicine in which drugs target
speciﬁc channels or even target the mechanism by which a
channel becomes dysfunctional.
Cerebellar dysfunction and ataxia
Mutations in ion channels can be associated with both episodic
and progressive ataxia syndromes—namely the episodic ataxia
syndromes and the spinocerebellar ataxias (SCAs; see online
supplemental table S2).
Episodic ataxias
There are two main forms of episodic ataxia—EA1 and EA2.
Both are dominantly inherited. Other rarer forms have been
reported in individual families.
EA1 is characterised by brief episodes of ataxia that last
seconds to minutes. The attacks begin in early childhood and
can be provoked by startle, vigorous activity, illness, hunger and
emotion.64 65 Cerebellar function is normal in between attacks,
but there may be persistent neuromyotonia of skeletal muscles
which can be conﬁrmed on electromyography (EMG).65 66
There is an increased incidence of epilepsy associated with
EA164 67 68 and there also have been reports of an increased
risk of hearing impairment.64 Recently, it has been found that
up to 20% of patients accumulate a persistent cerebellar syn-
drome.65 EA1 is caused by heterozygous, usually missense muta-
tions in the neuronal voltage-gated delayed rectiﬁer potassium
channel (KV1.1) gene KCNA1.
64 69 KV1.1 channels are fast
potassium channels widely expressed in the central nervous
system and in peripheral nerve where they regulate axonal excit-
ability.70 Different EA1-associated mutations of KCNA1 affect
channel function via diverse effects.68 71 Non-invasive excitabil-
ity studies on motor nerves in patients with EA1 can detect
changes speciﬁc to loss of fast potassium channel function in
vivo with high sensitivity and speciﬁcity.72 Recently, a novel
phenotype characterised by long-lasting attacks of jerking
muscle contractions associated with hyperthermia, migraine and
a short sleep phenotype was described in a patient with a single
nucleotide change in KCNA1.73
EA2 also presents with episodes of ataxia but these attacks
typically last longer than in EA1, lasting hours to days.74
Approximately 30–50% of patients develop a mild progressive
cerebellar ataxia and more than half report migrainous symp-
toms.74 75 One kindred with episodic ataxia has been shown to
also have absence epilepsy and dystonia has also been
reported.76 77 EA2 is caused by non-sense, frame shift, splice
site and missense mutations in the CACNA1A gene, which
encodes the pore-forming α1A subunit of CaV2.1—the
P/Q-type calcium channel.78 P/Q-type calcium channels are
widely expressed at synapses throughout the central and periph-
eral nervous systems, and have an important role in triggering
neurotransmitter release.79 Functional analysis has revealed dif-
ferent effects of EA2 mutations including altered channel func-
tion with reduced calcium current as well as effects on protein
folding and trafﬁcking.80–82
Treatment of episodic ataxia
Acetazolamide is often effective in EA2 and can be tried in
EA1, although in our experience it is less effective in EA1.83
4- Aminopyridine, a potassium channel blocker, has also been
reported in a double-blind randomised trial to have a prophylac-
tic effect on ataxia in EA2.84 The mechanism of action is incom-
pletely understood, but in animal studies, it was shown to
restore the diminished precision of pacemaking in Purkinje cells
of EA2 mutant mice by prolonging the duration of the action
potential.85
Spinocerebellar ataxias
At least three different ion channel genes have been implicated
in various forms of SCA including the calcium channel gene
CACNA1A and two potassium channel genes, KCNC3 and
KCND3. In contrast to many of the other inherited channelopa-
thies, the symptoms of cerebellar dysfunction in SCAs seem to
be predominantly progressive, rather than episodic.
SCA6 is allelic with EA2 and FHM type 1 and is caused by
expansions of the CAG repeat sequence in the 30 end of
CACNA1A.86 This is a late onset progressive cerebellar syn-
drome. Extracerebellar features are less prominent than in other
forms of SCA.87 The pathogenic mechanism of the polygluta-
mine repeat expansion in SCA6 is poorly understood. The basic
function of the P/Q channels are not affected in SCA6 knock in
mice, suggesting that the pathogenesis is related to an accumula-
tion of mutant CaV2.1 channels.
88
Some patients with EA2 have also been found to have small
CAG expansions in CACNA1A, thus leading to suggestions that
SCA6 and EA2 are a clinical continuum.89 Recently, mutations
in CACNA1A have been reported in three patients with parox-
ysmal tonic upgaze in association with motor and language
delay and cerebellar ataxia, thus widening the phenotype.90
Two voltage-gated potassium channel genes have been impli-
cated in other forms of SCA. Missense mutations in KCNC3,
which encodes KV3.3 have been found in patients with the
phenotype of SCA13, which may present as a neurodevelop-
mental disorder in infancy or an adult onset progressive cerebel-
lar syndrome depending on the causative mutation.91 92 KV3.3
channels are expressed in the cerebellum and have an important
role in fast repolarisation of neurons during high frequency
repetitive ﬁring.93
Mutations in the gene that codes for KV4.3, KCND3, have
been found in patients diagnosed with SCA19 and SCA22. Most
of the patients studied developed cerebellar symptoms around
middle age with a variable proportion developing extracerebel-
lar features such as cognitive impairment. Initial functional
studies suggest that mutations alter trafﬁcking of channels to the
cell membrane and also reduced channel function.94 95
No speciﬁc treatments have been demonstrated to be effective
in patients with progressive SCA.
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Migraine
Familial Hemiplegic Migraine (FHM) is a subtype of severe
migraine inherited in an autosomal dominant fashion. Patients
have severe auras that include unilateral weakness, as well as
visual, somatosensory or dysphasic symptoms, typically followed
or accompanied by migrainous headache.96 97 FHM is genetic-
ally heterogeneous and is classiﬁed into three types98 (see online
supplemental table S3).
FHM1 accounts for 75% of genetically conﬁrmed cases and is
caused by missense mutations in CACNA1A, the same gene that
is implicated in EA2 and SCA6.99 Functional expression studies
have shown that FHM mutations result in various gain of func-
tion effects, including increased CaV2.1 current density in cere-
bellar neurons and enhanced neurotransmitter release.96 FHM2
is caused by loss of function mutations in the ATP1A2 gene.
This gene encodes the α2 subunit of Na+/K+ pumps, which
contribute to maintaining transmembrane ion gradients.100
FHM3 is associated with heterozygous mutations in the sodium
channel gene SCN1A.101 This is the same gene that is associated
with seizure disorders. Why some mutations manifest as
migraine while others as epilepsy is not understood.
Knowledge of the molecular mechanisms of the different
forms of FHM have led to the suggestion that they can be
treated with acetazolamide or other agents that target ion chan-
nels such as verapamil and ﬂunarizine, which act on some
calcium channels, and lamotrigine, which acts on both sodium
and calcium channels.102 103 However, randomised evidence for
the efﬁcacy of any particular treatment is lacking.98
Familial hyperekplexia
Familial hyperekplexia—also known as hereditary startle disease
is characterised by neonatal hypertonia, hyper-reﬂexia, myo-
clonic jerks and an exaggerated startle response to sensory
stimuli. The hypertonicity and hyper-reﬂexia typically improve
during infancy but the exaggerated startle response continues
into adulthood.104
Mutations in GLRA1 account for 80% of hereditary hyperek-
plexia and are most commonly inherited in an autosomal dom-
inant fashion, although recessive and compound heterozygous
cases also occur.104 Missense, nonsense, frameshift and splice
site mutations, and large deletions have all been described.50 105
GLRA1 encodes the α subunit of the postsynaptic glycine recep-
tor chloride channel which mediates fast inhibition in the brain-
stem and spinal cord.104 Mutations impair glycine receptor
function, resulting in increased excitability in pontomedullary
reticular neurons and abnormal spinal reciprocal inhib-
ition.104 106 Hyperekplexia can also be caused by mutations in
the GLRB gene, which encodes the β subunit of the glycine
receptor, and in SLC6A5, which encodes the presynaptic glycine
transporter type 2.107–110 Clonazepam is the drug of choice as
it enhances GABAA receptor-mediated inhibition and was
shown in a randomised trial to signiﬁcantly reduce startle
activity.104 111
Inherited channelopathies of peripheral nerves
Ion channel disorders have implicated in various inherited dis-
eases of peripheral nerve including pain syndromes and neuro-
pathies (see online supplemental table S4).
Pain syndromes
Gene mutations in ion channels have been associated with
increased pain perception whereas other mutations cause
insensitivity to pain. Both ligand-gated and voltage-gated ion
channels have a pivotal role in the detection and transmission of
stimuli from nociceptors.
Point mutations in the sodium channel gene SCN9A which
codes for the α subunit of NaV1.7 channels have been associated
with two different pain syndromes associated with gain of func-
tion—primary erythromelalgia and paroxysmal extreme pain dis-
order.112 Nonsense mutations in the same gene have been
associated with a syndrome causing congenital insensitivity to
pain. NaV1.7 channels are expressed in dorsal root ganglion
(DRG) neurons where they regulate excitability of pain ﬁbres. A
different phenotype resulting from nonsense mutations in
SCN9A was described in two Japanese kindreds—hereditary
sensory and autonomic neuropathy type IID.113 These patients
had adolescent or congenital onset of loss of pain and tempera-
ture sensation and autonomic dysfunction with evidence of
reduction in sensory nerve action potentials on nerve conduc-
tion studies.
Primary erythromelalgia
PE is a rare syndrome characterised by intense burning pain,
usually of the extremities, with marked erythema and increased
skin temperature.114 Symptoms usually begin in the ﬁrst two
decades. Precipitating factors for pain include heat, exercise,
tight clothing and certain foods. The pain is initially episodic
but sometimes can become constant with ﬂuctuations.115
Mutations in the gene SCN9A which encodes the NaV1.7
sodium channel are typically inherited in an autosomal domin-
ant fashion and lower the voltage threshold for a sodium
current in dorsal root ganglia neurons, increasing their ﬁring
frequency in response to stimulation, slowing their activation
and increasing their response to slow ramp-like stimuli.116–119
Paroxsymal extreme pain disorder
Paroxsymal extreme pain disorder (PEPD) is a distinct syndrome,
previously known as familial rectal pain syndrome.120 The char-
acteristic feature is severe frequently visceral pain that affects
various parts of the body including the rectum and genitalia,
although the face and limbs can also be involved.121 The pain
can be associated with autonomic features including ﬂushing,
lacrimation, rhinorrhea and tonic attacks with apnoea and
bradycardia.122 123 Physical factors such as defecation and
eating can trigger attacks, as can emotion.115
In contrast to gain of function mutations in PE, functional
studies have shown that SCN9A mutations in PEPD impair the
fast inactivation of sodium channels leading to a persistent
sodium current.121
Treatment of painful channelopathies
Treatment of the painful channelopathies can be difﬁcult, as
patients do not respond to standard analgesics. Oral mexiletine
and topical lidocaine, both sodium channel blockers can be
effective in PE.124 Mexiletine is a non-selective sodium channel
blocker and has been shown to have a normalising effect on the
hyperpolarised channels seen in gain of function NaV1.7 muta-
tions.125 Patients often also use physical measures such as
immersing feet in cold water. Patients with PEPD may obtain
relief from carbamazepine which can help block the abnormal
persistent sodium currents due to impaired inactivation of
NaV1.7 seen in this disorder.
121
Congenital insensitivity to pain
In contrast to the above disorders which are autosomal domin-
ant, recessive, loss of function mutations of SCN9A result in
congenital insensitivity to pain.126 Patients develop repeated
Spillane J, et al. J Neurol Neurosurg Psychiatry 2016;87:37–48. doi:10.1136/jnnp-2015-311233 41
Neurogenetics
group.bmj.com on January 19, 2016 - Published by http://jnnp.bmj.com/Downloaded from 
painless fractures and injuries, which although painless can be
crippling.126 127 A mutation in the gene SCN11A which
encodes NaV1.9, a voltage-gated sodium channel primarily
expressed in nociceptors, has also been found in patients with
congenital insensitivity to pain; however in contrast to loss of
function SCN9A mutations in this condition, SCN11A muta-
tions are associated with a gain of function with sustained
depolarisation of nociceptors impeding the generation of action
potentials.128
Small ﬁbre neuropathy
The above disorders are rare diseases but recently gain of func-
tion missense variants in SCN9A that encodes the NaV1.7
channel have been found in approximately 30% of a cohort of
patients with idiopathic small ﬁbre neuropathy.129 Mutations in
the SCN10A and SCN11A genes which encode NaV1.8 and
NaV1.9, respectively, have also been described in a small
number of patients with painful peripheral neuropathy, suggest-
ing that inherited channelopathies may play a role in commonly
encountered clinical syndromes.130 131
Familial episodic pain syndrome
A different channel type is affected in familial episodic pain syn-
drome (FEPS), a rare dominantly inherited disorder132 charac-
terised by episodes of severe pain, triggered by cold and hunger,
localised principally to the upper body. It is caused by a gain of
function missense mutation in the TRPA1 gene, which encodes
TRPV1. TRPA1 is part of a family of transient receptor poten-
tial (TRP) channels, a large superfamily of cation channels.
TRPA1 is expressed in primary afferent nociceptors and plays
an important role in response to environmental irritants.133
A distinct type of FEPS has been described in two large Chinese
kindreds who were found to have mutations in SCN11A.134
Mutations in FEPS cause a gain of function with hyperexcitabil-
ity of the cells of the DRG.115
Motor and sensory neuropathies
Several inherited neuropathies that present mainly with motor
dysfunction are known to be due to ion channel dysfunction.
Three allelic disorders, Charcot-Marie-Tooth disease type IIC
(HSMNIIC), scapuloperoneal spinal muscular atrophy (SPSMA)
and congenital distal spinal muscular atrophy (SMA) are caused
by mutations in another class of TRP channel—the TRPV4
channels.135 136 HSMNIIC is an autosomal dominant axonal
neuropathy characterised by progressive distal limb weakness
and weakness of the diaphragm laryngeal muscles and vocal
cords.137 SPSMA manifests as progressive weakness of scapular
and peroneal muscles, laryngeal palsy and skeletal abnormal-
ities.138 Congenital distal SMA affects lower motor neurons
with variable disease severity ranging from congenital weakness
restricted to the distal lower limbs to more severe forms with
involvement of pelvic girdle and trunk muscles and arthrogry-
posis.135 TRPV4 encodes a channel that is broadly permeable to
cations including calcium, and can be activated by mechanical
stimuli, heat and endogenous and synthetic agonists. TRPV4 is
widely expressed in the brain and spinal cord.136 There is a lack
of consensus regarding the disease mechanism of TRPV muta-
tions causing neurological disease with both gain of function
and loss of function effects reported.137 139 140
Peripheral nerve hyperexcitability
Peripheral nerve hyperexcitability comprises a heterogeneous
group of diseases characterised by spontaneous and continuous
muscle activity (myokymia), muscle cramps, stiffness and
fasciculations.141 It is commonly seen as part of the EA1 pheno-
type resulting from mutations in KV1.1 potassium channels.
69 142
Mutations in the KV7.2 potassium channel gene (KCNQ2) asso-
ciated with BFNC have also been found to cause a genetic form
of peripheral nerve hyperexcitabililty.141 143
Congenital myasthenic syndromes
Congenital myasthenic syndromes (CMS) are a heterogeneous
group of genetic disorders that affect the neuromuscular junc-
tion. They are typically inherited in a recessive fashion and can
be caused by mutations in proteins of the neuromuscular junc-
tion that are presynaptic, synaptic or postsynaptic. Mutations in
over 15 different genes have been identiﬁed to date.144 Of rele-
vance to inherited channelopathies, the most common type of
CMS is caused by mutations in various genes encoding the sub-
units of muscle AChRs. Mutations in any one of the adult subu-
nits of the AChR channel can result in deﬁciency or kinetic
abnormality of the AChR145 (see online supplemental table S5).
Recessive mutations of CHRNA1, CHRNB1, CHRND and
CHRNE, which code for α1, β1, δ and ε subunits, respectively,
have all been implicated in primary AChR deﬁciency syndromes.
Mutations in the ε (epsilon) subunit are most frequently
encountered.144 Most patients with AChR deﬁciency syndromes
present with feeding problems, ptosis and ophthalmoplegia in
early infancy. Patients tend to respond well to pyridostigmine
and/or 3, 4-diaminopyridine (DAP), a potassium channel
blocker that prolongs the presynaptic action potential, thereby
enhancing ACh release.144 145
Other mutations can affect the kinetics of AChRs. Slow
channel syndrome is the only dominantly inherited CMS, and
can be caused by mutations in any of the AChR subunit genes.
The underlying pathology is a gain of function with sustained
activation of the AChR with either delayed channel closure or
enhanced ACh afﬁnity. This prolonged channel opening in turn
can result in an end-plate myopathy.146 Symptoms usually
present in childhood with delayed motor milestones and ocular
signs such as ptosis and ophthalmoplegia. It is important to rec-
ognise this syndrome as conventional treatment with pyridostig-
mine or 3, 4-DAP can worsen symptoms. Treatment is with
ﬂuoxetine or quinidine, both act as open channel blockers.147
Fast channel syndrome is a rare and severe form of CMS, in
which AChRs open for a shorter time than normal. It is asso-
ciated with loss of function mutations of AChR α1, δ and ε sub-
units. Children are typically affected from birth with respiratory
failure, feeding difﬁculties with ptosis and ophthalmoplegia.
Pyridostigmine and 3, 4-DAP may be beneﬁcial.144 146
Skeletal muscle channelopathies
The skeletal muscle channelopathies are a heterogeneous group
of disorders whose clinical manifestations range from ﬂaccid
paralysis to myotonia. They are divided into the non-dystrophic
myotonias (NDMs) and the periodic paralyses and are caused
by mutations in skeletal muscle ion channels that affect muscle
excitability (see online supplemental table S6).
Non-dystrophic myotonias
The NDMs are a group of skeletal muscle channelopathies that
present with myotonia (delayed muscle relaxation following vol-
untary contraction) without systemic features. This group of
conditions includes myotonia congenita (MC), paramyotonia
congenita (PMC) and the sodium channel myotonias (SCMs).
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Myotonia congenita
MC is the commonest of the skeletal muscle channelopathies148
and can be inherited in an autosomal dominant (Thomsen
disease) or recessive fashion (Becker disease). It is characterised
by muscle stiffness that predominantly affects the limbs.
Symptoms may be worsened by rest, infection or stress, and can
be accompanied by muscle hypertrophy. Patients often exhibit a
warm-up phenomenon when muscle stiffness improves with
repeated activity. Patients with recessive MC may also have tran-
sient weakness on the initiation of a movement.
MC is caused by mutations in the skeletal muscle chloride
channel CLCN1, which encodes the channel ClC-1.149 ClC-1
underlies the majority of the resting conductance of skeletal
muscle. Functional expression studies show that pathogenic
mutations can reduce the macroscopic chloride current, predis-
posing to muscle ﬁbre depolarisation and after-discharges.150
Typically, nonsense, missense and frame shift mutations that do
not affect the functional properties for the wild-type subunits in
the channel dimer are recessively inherited. Missense mutations
that shift the voltage dependence of activation out of the
physiological range are often dominantly inherited.151–154
Recessive mutations generally result in more severe symptoms.
Recently, it was found that up to 6% of patients with a recessive
family history but only one mutation in CLCN1 carry whole
exons or duplications in the CLCN1 gene, thus revealing a
novel genetic cause for recessive MC.155
PMC and SCMs
Two other groups of disorders characterised clinically by myo-
tonia are associated with sodium channel mutations—PMC and
the SCMs.
PMC presents as muscle stiffness early in life. However, in
contrast with MC, symptoms are worsened by exertion (para-
myotonia) and cold.156 PMC is also associated with episodes of
weakness, which can last for hours or days. In contrast, SCMs
are a subgroup of myotonic disorders that are characterised clin-
ically by pure myotonia without weakness. The severity of
SCMs is highly variable varying from a severe form with onset
in infancy to mild forms that only cause isolated eyelid myo-
tonia.157 The infantile forms can be associated with potentially
fatal laryngospasm highlighting the importance of genetic coun-
selling in affected adult patients with these disorders.156 157 The
presence of eyelid closure myotonia is speciﬁc for mutations in
SCN4A and can help to clinically differentiate this disorder
from MC.158
Both PMC and the SCMs are caused by dominantly inherited
mutations in the SCN4A, which encodes the skeletal muscle
voltage-gated sodium channel, NaV1.4. The same mutation has
been shown to cause either condition in different pedigrees.159
SCN4A mutations cause a gain of function effect on the
encoded α4 subunit of the muscle sodium channel NaV1.4.
They disrupt fast inactivation or cause a hyperpolarising shift in
the voltage dependence of activation.150 Recently, a small group
of patients with myotonia with heterozygous SCN4A mutations
and single CLCN1 mutations were described, widening the
genetic spectrum.160
Treatment of myotonia has improved considerably in recent
years. In vitro and animal studies have shown that the sodium
channel blocker mexiletine reduces muscle ﬁbre excitability
caused by common NDM mutation.161 162 A recent double-
blind, placebo-controlled crossover study of patients with NDM
conﬁrmed its efﬁcacy.163 Acetazolamide, which has been shown
to stabilise membrane excitability through a direct effect on the
chloride channel, has also been used and is particularly helpful
if there are concerns regarding the proarrhythmogenic side
effects of mexiletine.164 165 Experimental studies have suggested
that lacosamide and ranolazine, drugs that are used for epilepsy
and angina respectively, enhance slow in activation of sodium
channels and may be an alternative to mexiletine in patients
with MC.166 Other options include carbamazepine and pheny-
toin, although good-quality evidence is lacking.
Periodic paralyses
The inherited periodic paralyses are a group of disorders com-
prised of three conditions; hypokalaemic periodic paralysis
(Hypo PP), hyperkalaemic periodic paralysis (Hyper PP) and
Andersen-Tawil syndrome (ATS).
Hypokalemic periodic paralysis
Hypo PP is the most common form of periodic paralysis and is
characterised by episodes of ﬂaccid muscle weakness that occur
in association with a low serum potassium level. Attacks last
hours to days and typically affect the limbs; respiratory involve-
ment is rare. Precipitants include carbohydrate meals and rest
after exercise.156 With time, the frequency of attacks may dimin-
ish and a ﬁxed proximal weakness may develop.167 Hypo PP is
inherited in an autosomal dominant fashion but has a reduced
penetrance in women, a feature seen in several muscle channelo-
pathies. Causal mutations were ﬁrst identiﬁed in CACNA1S,
which encodes the α1S subunit of the skeletal muscle calcium
channel CaV1.1.
168 169 These account for approximately 80%
of cases. Mutations in the sodium channel gene SCN4A, also
associated with the SCMs, account for approximately 10% of
cases but up to 10–20% of cases remain genetically
undeﬁned.170
The overwhelming majority of mutations in Hypo PP,
whether in calcium or in sodium channels, occur in the voltage-
sensing region of the channel.171 How these lead to attacks of
paralysis has been a puzzle for many years. Recently, it has
emerged that the mutations open an abnormal cation leak
pathway through the voltage sensor itself, separate from the
main pore of the channel—the gating pore current.172 173 The
association of attacks with hypokalaemia is thought to reﬂect
the tendency for the inwardly rectifying potassium channel
Kir2.1 to fail to conduct when the extracellular potassium con-
centration is low.173–175
Recently, bumetanide, an inhibitor of the Na-K-2Cl
co-transporter was shown to prevent this paradoxical depolar-
isation in hypokalaemic conditions in animal studies and was
also shown to prevent attacks in mouse models of sodium and
calcium channel mutations.173 176 Clinical trials of bumetanide
for Hypo PP are starting.
Hyperkalaemic periodic paralysis
Hyper PP is characterised by episodes of muscle weakness in
association with elevated serum potassium. In addition to par-
alysis, myotonia may also be a feature.156 170 The attacks of par-
alysis are typically shorter than Hypo PP lasting minutes to
hours but can become prolonged with age, lasting up to 2
days.156 170 177 Hyper PP is caused by mutations in the sodium
channel gene SCN4A. The mutations in Hyper PP tend to
impair inactivation of the NaV1.4 sodium channel, leading to
persistent sodium inﬂux, depolarisation and inexcitability.178 179
Some Hyper PP mutations have also been shown to shift the
voltage dependence of activation in the negative direction,
allowing channels to open sooner.180 The association with
hyperkalaemia probably reﬂects in part a positive feedback loop,
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whereby depolarisation leads to potassium efﬂux, which results
in a further depolarisation.181
Andersen-Tawil syndrome
ATS is a rare disorder characterised by a triad of periodic paraly-
sis, cardiac defects and skeletal abnormalities, although not
every patient will have all three features.182 The periodic paraly-
sis is typically associated with low levels of potassium but can be
associated with normokalaemia or hyperkalaemia. Cardiac
abnormalities seen include enlarged U waves, a prolonged QUC
interval and ventricular arrythymias.183 Cardiac arrest occurs in
approximately 10% of patients with ATS and cardiac screening
is mandatory.184 185 Distinctive facial features seen in ATS
include micrognathia, low set ears, hypertelorism, clindactyly
and syndactyly.185 ATS is caused by mutations in the coding
exon 2 of the KCNJ2 gene which encodes the inward rectifying
potassium channel Kir2.1.186 These channels contribute to the
resting membrane potential in the heart, brain and skeletal
muscle.
No current through Kir2.1 channels is seen when mutant
KCNJ2 channels are expressed in vitro. Co-expression of wild-
type channels with mutant channels results in reduction in
inward rectifying currents indicating a dominant negative effect
of the mutation.186 187 Up to 10% or 20% of patients will not
have a mutations in KCNJ2.184 Recently, mutations in KCNJ5,
the gene encoding Kir 3.4 was found to cause ATS in a patient
with typical muscle and cardiac features but without
dysmorphism.188
Treatment of the periodic paralyses
Management of periodic paralysis rests on trigger avoidance.
Oral potassium can speed attack resolution in Hypo PP whereas
ingestion of sweets and mild exercise can hasten attack reso-
lution in Hyper PP. Inhaled salbutamol has also been shown to
be effective in treating attacks of Hyper PP.189 Occasionally,
prophylactic treatment is required. Acetazolamide is often a
ﬁrst-line treatment for both Hyper PP and Hypo PP. It has been
shown to increase muscle strength and endurance in a small ran-
domised controlled trial.190 Dichlorphenamide was shown to
reduce attack frequency in a double-blind, placebo-controlled
trial in Hyper PP and Hypo PP.191 An additional option in
Hypo PP includes potassium-sparing diuretics such as spirono-
lactone or amiloride.156 Pinacidil, a potassium channel agonist,
was found to improve muscle strength in a small randomised
controlled trial.192
Electrophysiology in skeletal muscle channelopathies
The functional consequences of ion channel mutations in skel-
etal muscle can be examined by electrophysiology. Myotonia on
needle EMG is seen in all forms of NDM but severity can vary
and the duration of myotonic discharges on EMG can be used
to distinguish sodium and chloride channel myotonias.193 194
Measurement of compound action potential amplitudes before
and after exercise, the short and long exercise test, helps to dis-
tinguish between the different skeletal muscle channelopathies.
MRI in skeletal muscle channelopathies
MRI has recently been developed for diagnosis and monitoring
use in skeletal muscle channelopathies. A hyperintense central
stripe in the medial gastrocnemius muscle appears to be speciﬁc
for NDM, particularly MC.195 Fatty inﬁltration of muscles can
also be seen on MRI which is consistent with the clinical obser-
vation of ﬁxed weakness in some patients over time.177 Patients
with Hypo PP who have permanent weakness are also found to
have fatty muscle replacement on MRI. An increase in 23Na+
MRI signal intensity can seen in patients with Hypo PP suggest-
ing muscle oedema which can be reduced by acetazolamide
treatment, indicating that muscle imaging is likely to play an
increasing role in therapy monitoring in the future.175
Thyrotoxic periodic paralysis
Thyrotoxic periodic paralysis is a rare condition causing attacks
indistinguishable from Hypo PP but in the presence of thyro-
toxicosis. The disorder is most common in young Asian and
Latin American men in whom 10% of thyrotoxic males develop
episodic weakness.190 Candidate gene sequencing has revealed
mutations in KCNJ18 which encodes Kir 2.6, an inwardly recti-
fying potassium channel that is expressed in skeletal muscle and
transcriptionally regulated by thyroid hormones in one-third of
patients.196
CONCLUSION
Although individually rare, the inherited channelopathies can be
accurately diagnosed by careful clinical assessment and
DNA-based diagnosis. An accurate diagnosis is important for
genetic counselling and to direct treatment options. Recent
molecular genetic advances have provided insights into patho-
physiological mechanisms that are potentially relevant to more
common paroxysmal disorders such as epilepsy and migraine.
Ion channels are an attractive target for investigation of these
common diseases with polygenic inheritance. However, to date,
genetic association studies have not revealed clear mechanistic
understanding, possibly because of the complexity of elucidating
the effect of multiple genetic channel variation interactions. The
increased use of whole genome sequencing is generating very
large amounts of genetic data including variations in ion
channel genes. However, extensive biophysical characterisation
in representative model systems will be required to determine
the contribution of different variants to common paroxysmal
neurological diseases.
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